report growth thrilled quarterly Therapeutics continues our double-digit you, Dewey. highest that United Thank revenue I'm revenue ever. and to
business, expect by run as expect growth reach current $X billion with revenue mid-decade. trajectory to to rate annual a we this our We continue,
doubling in organs revenue of the that, waves additional potential doubling potential we transplantable our an Tyvaso the of in hypertension pulmonary with of supply and unlimited pulmonary our ralinepag an next continued decade. the with in fibrosis yet of revenues from arterial Beyond of another expect tolerable for of and launch growth then
these me bit that this Let pleased results some are we quarter. of little a report fantastic to deeper absolutely into now drive
total of at compare million months. last about As mentioned, the three $XXX to matching the But months $XXX were three which are with revenues for year, interesting the that million. it's just
expect revenue very the that's So rate by and that much growth to of achieve that $X achieve to billion with we order type of a percentage line we mid-decade. growth rate XX% in indicated previously in rate have run
look Another net the income. deeper level to company's at is
$XXX $X.XX reported that reported compare For past we over with quarter it's And in net million again, of matching a income billion XXXX, in quarter, the percentage change when instructive the net income. we -- quarter XXX%. to in
comparable compared Very into outstanding, net a those we're we fantastic the helps of divide numbers shares as peers pretty low you number results. to relatively that which income fact, have can And shares. the proud if in be drive obtained, outstanding
the on results last the Tyvaso million $XX from million, Orenitram $XXX the last matching XX% about year. last Remodulin matching from from the $XX of from Unituxin year. products. quarter million year. some flat quarter quarter into down essentially up matching million, deeper, even $X dive the $XXX let's XX% Now up year. million, last
used miracle of their other pediatric checked XX% rate they're neuroblastoma, returned treat I Unituxin should it as Unituxin the are about for high everyone, a is of treated concomitant has remarkable, cancer out who half to as that the -- that kids for mortality. here that and live therapies been not that that talk devastating but kids getting Therapeutics, I probably a approximately United not biotechnology patients. people tender perhaps that cancer Therapeutics, blessings a the and to the well Even for life, about by years. with cancer, that several in cancer-free based be very years And return. a with one in many the the years so of on really used, when doctors later, has a stop newer the many of at of just does treatment this remind to United after can wiped find and don't cancer much five their is truly We Unituxin, diagnosis
it's on drug So in well a close so that pediatric now annualized to used basis getting $XXX any event million, the an at is because year. we're looking by oncologists,
profit those in to Now addition, figures. top and line revenues
Let's large few categories, dive and out then development in internal research the external little spending general spending research bit into And in break a miscellaneous administrative section. and our and sales GAAP development, we with to standards. a marketing of there the put and according and categories, in terms here rows
research we our with development. lion's spend our companies of other conducting what trials. clinical money is, to development assisting and research share external on the and goes that worldwide The So us
trials the of a development, is the which going most III now, of largest and Phase So, and phase on them most development. stage few clinical right got of the we've quite costly are in
have Phase pulmonary we have type And also or fibrosis. and idiopathic new trials another We then trial of starting year. Phase X TETON for is III two X which the this up X this III PPF TETON just fibrosis, called TETON pulmonary
we in covering that trial, and hypertension. in clinical every pulmonary We is have death Ralinepag trial more a countries with morbidity worldwide continent. reduce that clinical is expensive aiming endpoint almost an patients, for that trials clinical show And because the ongoing to
rates. going treated to statistically and then significant until respect enroll study patients in active with And difference the we look the both to group. we and have at death longer, get achieve keep significance, that to we statistical or more a the our So, hope
with We also trial. ongoing gene the still are therapy
about just spending inside in million, spending And the year, combined, talking end outside they company. a more so that's and all of the of company these us than of level costing the of trials not even up $XXX
of clinical I people checklist to protocol tell sure effort complied be the get to drug Now amount the you she constantly make on these the takes it labeled, doing inside Phase to call who led of every shipped job Dr. all clinical just amazing how we've begin And been our translated, -- simultaneously. got by ultimately over great running sending long countries month trials X of of joins an being trials. to conduct really these is that those is with. it of humongous cannot to a And drug world, all today. the centers, the me these monitoring company team Peterson there amazing, developers has
surprising spent not $XXX on that it's research million more is and So than another there a internal year development.
transplantation cover got the activities under internal I and manufacturing there the xenoheart. lead for we and the described category, we the development Now meetings they're accordance in FDA guidance, program with And efforts both in efforts. Xeno organ research received the beginning for for at interact call. our development that our FDA we've And xenokidney also the the which of the with the the
the an xenokidney opening We pivotal of studies xenoheart. an to necessary enable preclinical IND and for are proceeding with
not best our case really to that IND would it frame. a that be to was is for doing a be It's pessimistic soon are of that. appropriate open possible. feel FDA FDA reasonable as XXXX-XXXX decision the case as We the exactly able the frame that kind when time I possible a to to predict do But frame more XXXX-XXXX would time that could time say time hopefully
an corner that's drug additional area you around spend. literally development speak. significant look at And the anyway But in it, it is of
with both that have We hypertension them where needs patients pulmonary which heavily treated manufacturing our also those disease transplant. laboratory with been for doing as too who and on cellularization. transplant. progresses, as hypertension. you as a to our is usually to pulmonary other are lung to continuing laboratory-based progress lung point medicines activities with autologous allogeneic really course manufactured matter trailblazing a spend effort able the fibrosis lungs our their that patients' that of we of well lung pulmonary the the But well needing have and event best satisfy for And is in many to of own diseases, our for people are case be lung many to with And
very have needs the And program, remarkable a the sick to we lung or surgeons feel transplant from But are lungs who use in ready organ certain want take meantime a -- really bioengineering. this donors which they very, various lung lung. quite that for person reasons into we call put to not program that we in for they donor that who
campus and those So Silver procurement Spring, lung the organ is street is they from organizations Florida to on Jacksonville, of centers. the our the across the Maryland of lungs Clinic. asked in to headquarters in One two Mayo the fly bioengineering other our one
to like patient or work a And to actually lung highly -- transplantation. surgeon a person away Again, to a trained everything they would doctor can render that they me be lung save the save that going be to procedure, person's blown who's a time that half as able quite person's to a used not there a on technicians. are suitable like like skilled person do to on lung a the life. fact is done never highly that would in on was life they for of They work succeed I'm the as a patient. used work And would a and
lung these products. have And over bioengineering people's with lives to-date saved we XXX
I'll allogeneically use in we just a of life, to are lungs from kind not the to to assist person's cellularized able oftentimes mention in lung able also are the manufacture cells we our when to that laboratories. lung the coincidentally efforts save our use to
fits of kind United Therapeutics. it's So here together everything all at
but so quite know at for a going on just talked I many United there is exciting on Therapeutics. things here while I've
to a of we able that three targeting been areas deployment. are cash have substantial We up main balance for build and
them we my foremost invest mentioned the I've Therapeutics. at is here have and And of all today. projects several going of that First to remarks in internal United in
talked in facility You about Research Triangle production recall, we of last to on production campus Park, $X.X DPI our Tyvaso may the dedicated North quarter billion being a just allocated Carolina.
DPI recognition regard. in excellent patients that the So in among their and very that Tyvaso all the of seen is that families, patients has physicians, the product supporting take-up
and wants for And and name that equivalent production I then totally animal would previously. those the of designated a FDA see the a manufactured be for a another that course, GMP the appropriate see and area of facility. in The xenokidneys it to equivalent capital xenohearts we want would the clinically requires to deployment of xenohearts pathogen-free facilities fashion, facility. also xenokidneys which is are build And to mentioned GMP technical
also capital that. for is targeted So
capital our business candidates compelling for very those acquisition, is for she In addition, adequate of and we have outright development need a Dr. either by us frequently potential very group Betsy or often opportunities. to led to And company. robust Eades we bringing retain investment
that You $X I biggest pulmonary the recall may for we acquired ralinepag drug next our could business have in development through that hypertension impact about think probably was efforts billion.
of being opportunities by these reviewed are type So Dr. regularly Eades.
repurchase to be is third external excess shares to business then deployed development that the can't And business for internal that there extent development. or capital is
would repurchased share to next time. be engage shares of Of step the in over we lots and course, have repurchases
I in is because modest fact, part In our mentioned share share peers previous is compared outstanding relatively count that our that no to small repurchase. earlier and
Officer. So I'd to turn Chief like our over Operating Michael the introductory with Mike? President those to remarks, phone now and Benkowitz,
